Private Wealth Partners LLC Has $11.30 Million Position in Zoetis Inc. $ZTS

Private Wealth Partners LLC reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,462 shares of the company’s stock after selling 4,050 shares during the period. Zoetis accounts for approximately 0.9% of Private Wealth Partners LLC’s investment portfolio, making the stock its 29th biggest holding. Private Wealth Partners LLC’s holdings in Zoetis were worth $11,300,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after acquiring an additional 189,287 shares during the period. Polen Capital Management LLC grew its holdings in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Northern Trust Corp grew its holdings in Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the period. Goldman Sachs Group Inc. grew its holdings in Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after acquiring an additional 109,791 shares during the period. Finally, Brown Advisory Inc. grew its holdings in Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after acquiring an additional 312,746 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ZTS shares. Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, UBS Group reduced their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday, October 20th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $195.00.

Zoetis Price Performance

Shares of NYSE ZTS opened at $147.57 on Tuesday. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $184.40. The stock has a market cap of $65.40 billion, a price-to-earnings ratio of 25.40, a PEG ratio of 2.35 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm’s 50-day simple moving average is $148.08 and its 200 day simple moving average is $153.52.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter last year, the firm earned $1.56 EPS. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is presently 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.